DURECT CORP
DURECT CORP (DRRX): 2 pipeline candidates · ~12 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
11.9 months
N/A
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for DURECT CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$6.7M
Quarterly Burn
$1.8M
Runway
11.9 mo
Revenue
$447K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| larsucosterol | Phase 2 |
| posimir | Approved |
Frequently asked questions
How many drug candidates are in DURECT CORP's pipeline?
DURECT CORP (DRRX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is DURECT CORP's lead drug candidate?
DURECT CORP's most advanced tracked candidate is larsucosterol (Phase 2) for Alcohol-associated hepatitis (AH).
What is DURECT CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, DURECT CORP has approximately 11.9 months of cash runway.
Who is the CEO of DURECT CORP?
James E. Brown is the chief executive officer of DURECT CORP (DRRX).
Get the full picture on DURECT CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.